Tenofovir is less toxic than other nucleoside reverse-transcriptase inhibitors used in antiretroviral therapy (ART) and may improve retention of human immunodeficiency virus (HIV)–infected patients on ART.
Zambia
Resource
November 19, 2019
Resource
October 25, 2019
BACKGROUND: A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infectio
Resource
October 23, 2019
INTRODUCTION: HIV testing male partners of pregnant and postpartum women can lead to improved health outcomes for women, partners and infants.
Resource
October 10, 2019
In this issue of the research Digest, we have assembled 86 abstracts published in July and August 2019 that feature evidence from Botswana (4), Burundi (1), Democratic Republic of Congo (1), Eswatini (3), Lesotho (4), Malawi (3), Mozambique (7), South Africa (51), Zambia (10) and Zimbabwe (9). Abstracts are grouped into linked categories to make browsing easier: Advocates (1); Health care providers (14); implementers and programmers (37); lay health workers (2); policymakers and government officials (1); and researchers (31).
Resource
October 7, 2019
The study has demonstrated that decentralizing phlebotomy services within the CAG model has greater potential to improve the quality of services delivery for patients. In addition, it has perceived threats on the quality of specimen collected, patient's safety, and health care.
Resource
July 30, 2019
mothers2mothers (m2m) is an African NGO working towards the Global Goals of ensuring good health for all and ending the AIDS epidemic by 2030.
Resource
July 16, 2019
Our 9th Research Digest assembles 87 abstracts published from May through June 2019 that feature evidence from Botswana (6), Eswatini/Swaziland (2), Malawi (12), Mozambique (4), South Africa (46), Tanzania (4), Zambia (7) and Zimbabwe (17).
Resource
July 16, 2019
BACKGROUND: Sub-Saharan African correctional facilities concentrate large numbers of people who are living with HIV or at risk for HIV infection.
News
June 26, 2019
Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.
Resource
June 25, 2019
Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform women's decision making, provider counselling, and policy maker and regulatory decisions. Our primary objective was to compare HIV incidence among women using DMPA-IM, a copper IUD, or a levonorgestrel (LNG) implant.
